MA44518A - Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin - Google Patents

Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin

Info

Publication number
MA44518A
MA44518A MA044518A MA44518A MA44518A MA 44518 A MA44518 A MA 44518A MA 044518 A MA044518 A MA 044518A MA 44518 A MA44518 A MA 44518A MA 44518 A MA44518 A MA 44518A
Authority
MA
Morocco
Prior art keywords
subject
needs
angiogenesis inhibition
inhibition processes
processes
Prior art date
Application number
MA044518A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Larry Tjoelker
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of MA44518A publication Critical patent/MA44518A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA044518A 2016-03-31 2017-03-31 Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin MA44518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662315857P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
MA44518A true MA44518A (fr) 2019-02-06

Family

ID=59959191

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044518A MA44518A (fr) 2016-03-31 2017-03-31 Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin

Country Status (20)

Country Link
US (3) US10870708B2 (fr)
EP (1) EP3436072A4 (fr)
JP (3) JP6865767B2 (fr)
KR (4) KR20250007026A (fr)
CN (3) CN117582494A (fr)
AU (2) AU2017240129B2 (fr)
BR (1) BR112018069732A2 (fr)
CA (2) CA3018774C (fr)
CL (1) CL2018002708A1 (fr)
EA (2) EA201892218A1 (fr)
GE (2) GEAP202214913A (fr)
IL (2) IL262021B2 (fr)
MA (1) MA44518A (fr)
MX (2) MX2018011648A (fr)
MY (1) MY195432A (fr)
NZ (1) NZ745531A (fr)
PH (1) PH12018502046B1 (fr)
SG (2) SG10202009886SA (fr)
WO (1) WO2017173290A1 (fr)
ZA (1) ZA202500956B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731596A (en) * 2011-04-08 2022-07-01 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
WO2019231935A1 (fr) 2018-05-29 2019-12-05 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11471729B2 (en) 2019-03-11 2022-10-18 Rom Technologies, Inc. System, method and apparatus for a rehabilitation machine with a simulated flywheel
US12029940B2 (en) 2019-03-11 2024-07-09 Rom Technologies, Inc. Single sensor wearable device for monitoring joint extension and flexion
US11433276B2 (en) 2019-05-10 2022-09-06 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength
US11801423B2 (en) 2019-05-10 2023-10-31 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to interact with a user of an exercise device during an exercise session
US11904207B2 (en) 2019-05-10 2024-02-20 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains
US11957960B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies Inc. Method and system for using artificial intelligence to adjust pedal resistance
US11957956B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies, Inc. System, method and apparatus for rehabilitation and exercise
US12102878B2 (en) 2019-05-10 2024-10-01 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to determine a user's progress during interval training
US11833393B2 (en) 2019-05-15 2023-12-05 Rehab2Fit Technologies, Inc. System and method for using an exercise machine to improve completion of an exercise
US11896540B2 (en) 2019-06-24 2024-02-13 Rehab2Fit Technologies, Inc. Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy
US11071597B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Telemedicine for orthopedic treatment
US12402804B2 (en) 2019-09-17 2025-09-02 Rom Technologies, Inc. Wearable device for coupling to a user, and measuring and monitoring user activity
US12420143B1 (en) 2019-10-03 2025-09-23 Rom Technologies, Inc. System and method for enabling residentially-based cardiac rehabilitation by using an electromechanical machine and educational content to mitigate risk factors and optimize user behavior
US11317975B2 (en) 2019-10-03 2022-05-03 Rom Technologies, Inc. Method and system for treating patients via telemedicine using sensor data from rehabilitation or exercise equipment
US11515021B2 (en) 2019-10-03 2022-11-29 Rom Technologies, Inc. Method and system to analytically optimize telehealth practice-based billing processes and revenue while enabling regulatory compliance
US11955220B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine
US12555667B2 (en) 2019-10-03 2026-02-17 Rom Technologies, Inc. Systems and methods for using AI/ML and for cardiac and pulmonary treatment via an electromechanical machine related to urologic disorders and antecedents and sequelae of certain urologic surgeries
US11887717B2 (en) 2019-10-03 2024-01-30 Rom Technologies, Inc. System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine
US12176089B2 (en) 2019-10-03 2024-12-24 Rom Technologies, Inc. System and method for using AI ML and telemedicine for cardio-oncologic rehabilitation via an electromechanical machine
US12100499B2 (en) 2020-08-06 2024-09-24 Rom Technologies, Inc. Method and system for using artificial intelligence and machine learning to create optimal treatment plans based on monetary value amount generated and/or patient outcome
US11978559B2 (en) 2019-10-03 2024-05-07 Rom Technologies, Inc. Systems and methods for remotely-enabled identification of a user infection
US12020799B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. Rowing machines, systems including rowing machines, and methods for using rowing machines to perform treatment plans for rehabilitation
US11069436B2 (en) 2019-10-03 2021-07-20 Rom Technologies, Inc. System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks
US11915815B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated
US12062425B2 (en) 2019-10-03 2024-08-13 Rom Technologies, Inc. System and method for implementing a cardiac rehabilitation protocol by using artificial intelligence and standardized measurements
US12230381B2 (en) 2019-10-03 2025-02-18 Rom Technologies, Inc. System and method for an enhanced healthcare professional user interface displaying measurement information for a plurality of users
US11282599B2 (en) 2019-10-03 2022-03-22 Rom Technologies, Inc. System and method for use of telemedicine-enabled rehabilitative hardware and for encouragement of rehabilitative compliance through patient-based virtual shared sessions
US11270795B2 (en) 2019-10-03 2022-03-08 Rom Technologies, Inc. Method and system for enabling physician-smart virtual conference rooms for use in a telehealth context
US12562243B2 (en) 2019-10-03 2026-02-24 Rom Technologies, Inc. System and method for processing medical claims using biometric signatures
US11955221B2 (en) * 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis
US12150792B2 (en) 2019-10-03 2024-11-26 Rom Technologies, Inc. Augmented reality placement of goniometer or other sensors
US20230245750A1 (en) 2019-10-03 2023-08-03 Rom Technologies, Inc. Systems and methods for using elliptical machine to perform cardiovascular rehabilitation
US11282608B2 (en) 2019-10-03 2022-03-22 Rom Technologies, Inc. Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in or near real-time during a telemedicine session
US11075000B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Method and system for using virtual avatars associated with medical professionals during exercise sessions
US12548656B2 (en) 2019-10-03 2026-02-10 Rom Technologies, Inc. System and method for an enhanced patient user interface displaying real-time measurement information during a telemedicine session
US12380984B2 (en) 2019-10-03 2025-08-05 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to generate treatment plans having dynamically tailored cardiac protocols for users to manage a state of an electromechanical machine
US12420145B2 (en) 2019-10-03 2025-09-23 Rom Technologies, Inc. Systems and methods of using artificial intelligence and machine learning for generating alignment plans to align a user with an imaging sensor during a treatment session
US11139060B2 (en) 2019-10-03 2021-10-05 Rom Technologies, Inc. Method and system for creating an immersive enhanced reality-driven exercise experience for a user
US12347543B2 (en) 2019-10-03 2025-07-01 Rom Technologies, Inc. Systems and methods for using artificial intelligence to implement a cardio protocol via a relay-based system
US12327623B2 (en) 2019-10-03 2025-06-10 Rom Technologies, Inc. System and method for processing medical claims
US12539446B2 (en) 2019-10-03 2026-02-03 Rom Technologies, Inc. Method and system for using sensors to optimize a user treatment plan in a telemedicine environment
US11961603B2 (en) 2019-10-03 2024-04-16 Rom Technologies, Inc. System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine
US12020800B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. System and method for using AI/ML and telemedicine to integrate rehabilitation for a plurality of comorbid conditions
US11282604B2 (en) 2019-10-03 2022-03-22 Rom Technologies, Inc. Method and system for use of telemedicine-enabled rehabilitative equipment for prediction of secondary disease
US12224052B2 (en) 2019-10-03 2025-02-11 Rom Technologies, Inc. System and method for using AI, machine learning and telemedicine for long-term care via an electromechanical machine
US12427376B2 (en) 2019-10-03 2025-09-30 Rom Technologies, Inc. Systems and methods for an artificial intelligence engine to optimize a peak performance
US12469587B2 (en) 2019-10-03 2025-11-11 Rom Technologies, Inc. Systems and methods for assigning healthcare professionals to remotely monitor users performing treatment plans on electromechanical machines
US12478837B2 (en) 2019-10-03 2025-11-25 Rom Technologies, Inc. Method and system for monitoring actual patient treatment progress using sensor data
US12191018B2 (en) 2019-10-03 2025-01-07 Rom Technologies, Inc. System and method for using artificial intelligence in telemedicine-enabled hardware to optimize rehabilitative routines capable of enabling remote rehabilitative compliance
US11087865B2 (en) 2019-10-03 2021-08-10 Rom Technologies, Inc. System and method for use of treatment device to reduce pain medication dependency
US12220201B2 (en) 2019-10-03 2025-02-11 Rom Technologies, Inc. Remote examination through augmented reality
US11101028B2 (en) 2019-10-03 2021-08-24 Rom Technologies, Inc. Method and system using artificial intelligence to monitor user characteristics during a telemedicine session
US11325005B2 (en) 2019-10-03 2022-05-10 Rom Technologies, Inc. Systems and methods for using machine learning to control an electromechanical device used for prehabilitation, rehabilitation, and/or exercise
US11955223B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions
US12154672B2 (en) 2019-10-03 2024-11-26 Rom Technologies, Inc. Method and system for implementing dynamic treatment environments based on patient information
US11955222B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria
US12230382B2 (en) 2019-10-03 2025-02-18 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to predict a probability of an undesired medical event occurring during a treatment plan
US11923065B2 (en) 2019-10-03 2024-03-05 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine
US11915816B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states
US11265234B2 (en) 2019-10-03 2022-03-01 Rom Technologies, Inc. System and method for transmitting data and ordering asynchronous data
US12246222B2 (en) 2019-10-03 2025-03-11 Rom Technologies, Inc. Method and system for using artificial intelligence to assign patients to cohorts and dynamically controlling a treatment apparatus based on the assignment during an adaptive telemedical session
US11826613B2 (en) 2019-10-21 2023-11-28 Rom Technologies, Inc. Persuasive motivation for orthopedic treatment
US12562271B2 (en) 2019-11-06 2026-02-24 Rom Technologies, Inc. System for remote treatment utilizing privacy controls
US12424319B2 (en) 2019-11-06 2025-09-23 Rom Technologies, Inc. System for remote treatment utilizing privacy controls
CA3159172A1 (fr) 2019-12-04 2021-06-10 Michael Cicirelli Inhibiteurs de masp-2 et procedes d'utilisation
EP4069238A1 (fr) 2019-12-04 2022-10-12 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
EP4069676A1 (fr) 2019-12-04 2022-10-12 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
AU2020397894B2 (en) * 2019-12-04 2025-02-20 Omeros Corporation MASP-2 inhibitors and methods of use
US11107591B1 (en) 2020-04-23 2021-08-31 Rom Technologies, Inc. Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts
US12357195B2 (en) 2020-06-26 2025-07-15 Rom Technologies, Inc. System, method and apparatus for anchoring an electronic device and measuring a joint angle
KR102846753B1 (ko) 2020-09-04 2025-08-13 주식회사 엘지에너지솔루션 배터리 관리 장치 및 방법
US12367960B2 (en) 2020-09-15 2025-07-22 Rom Technologies, Inc. System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine
US12515104B2 (en) 2020-10-28 2026-01-06 Rom Technologies, Inc. Systems and methods for using machine learning to control a rehabilitation and exercise electromechanical device
PY22106817A (es) 2021-12-10 2023-12-21 Omeros Corp Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Masp-2阻害物質としての縮合ピリミジン
US12216123B2 (en) 2023-04-25 2025-02-04 Nuvance Health Extracellular vesicle derived MASP-2 directed cancer treatment methods
WO2024226573A2 (fr) * 2023-04-25 2024-10-31 Nuvance Health Méthodes de traitement du cancer dirigé par masp-2
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1989005852A1 (fr) 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1531757B1 (fr) 2002-07-19 2016-09-07 Omeros Corporation Copolymeres triblocs biodegradables, procedes de synthese, et hydrogels et biomateriaux fabriques a partir de ces derniers
PL2374819T3 (pl) 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US11130801B2 (en) * 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
NZ731596A (en) * 2011-04-08 2022-07-01 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
MX347691B (es) 2011-05-04 2017-05-09 Omeros Corp Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
BR112013033272A2 (pt) * 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
CN115040653A (zh) * 2012-06-18 2022-09-13 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法
CN105683219B (zh) * 2013-10-17 2020-07-14 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
JP6369862B2 (ja) 2014-08-06 2018-08-08 原 英彰 眼内血管新生抑制剤及びその用途

Also Published As

Publication number Publication date
SG11201808242UA (en) 2018-10-30
MY195432A (en) 2023-01-20
AU2020201633A1 (en) 2020-03-19
NZ745531A (en) 2020-09-25
JP2022110159A (ja) 2022-07-28
ZA202500956B (en) 2025-06-25
PH12018502046A1 (en) 2019-07-08
MX2018011648A (es) 2019-01-30
KR20200113290A (ko) 2020-10-06
AU2020201633B2 (en) 2022-03-31
KR20180128941A (ko) 2018-12-04
EA202191185A1 (ru) 2021-10-29
BR112018069732A2 (pt) 2019-02-05
IL262021B1 (en) 2023-09-01
EP3436072A1 (fr) 2019-02-06
IL262021A (en) 2018-10-31
GEAP202214913A (en) 2022-09-26
EP3436072A4 (fr) 2019-11-06
IL305200A (en) 2023-10-01
GEP20237466B (en) 2023-01-25
AU2017240129B2 (en) 2020-04-02
IL262021B2 (en) 2024-01-01
MX2022012380A (es) 2022-10-31
KR20230019991A (ko) 2023-02-09
EA201892218A1 (ru) 2019-03-29
NZ762159A (en) 2025-05-02
JP2019513715A (ja) 2019-05-30
CA3018774A1 (fr) 2017-10-05
US11981748B2 (en) 2024-05-14
CA3096270C (fr) 2024-05-21
SG10202009886SA (en) 2020-11-27
KR20250007026A (ko) 2025-01-13
CN117582494A (zh) 2024-02-23
CN109152834A (zh) 2019-01-04
US20210189009A1 (en) 2021-06-24
WO2017173290A1 (fr) 2017-10-05
JP6865767B2 (ja) 2021-04-28
CA3018774C (fr) 2023-02-28
US20170283508A1 (en) 2017-10-05
IL305200B1 (en) 2025-11-01
CN115137816A (zh) 2022-10-04
US20240352152A1 (en) 2024-10-24
CL2018002708A1 (es) 2019-01-11
US10870708B2 (en) 2020-12-22
AU2017240129A1 (en) 2018-09-06
PH12018502046B1 (en) 2024-01-24
JP2020125332A (ja) 2020-08-20
CA3096270A1 (fr) 2017-10-05

Similar Documents

Publication Publication Date Title
MA44518A (fr) Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin
EP3529524A4 (fr) Dispositif de déplacement de tuyau d'alimentation en béton à roues
EP3849533A4 (fr) Procédés d'inhibition
UA33118S (uk) Підвіска «коловрат із зіркою русі»
IL249690A0 (en) The clean collar sticker
UA31429S (uk) Підвісок «воля віри»
UA33828S (uk) Емблема «мегамастер»
GB201620146D0 (en) Concept 36 A
GB201620178D0 (en) Concept 36 A
GB201620148D0 (en) Concept 37
GB201620126D0 (en) Concept 138
GB201620128D0 (en) Concept 51
GB201620129D0 (en) Concept 53
GB201617551D0 (en) Concept 134
GB201616434D0 (en) Concept 133
UA32360S (uk) Логотип «f1»
GB201616142D0 (en) Concept 132
GB201614417D0 (en) Concept 129
GB201614312D0 (en) Concept 125
GB201614306D0 (en) Concept 129
GB201614311D0 (en) Concept 22
GB201614310D0 (en) Concept 126
GB201614305D0 (en) Concept 123
UA32472S (uk) Емблема «steel»
GB201613364D0 (en) Concept 118